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Plasma components, such as fresh frozen plasma (FFP), fresh 
plasma, frozen plasma, and cryoprecipitates, are commonly 
used for the correction of bleeding due to the deficiency 
of blood coagulation factors. Furthermore, blood coagulation 
factors and plasma proteins are components of plasma that 
enable the manufacture of plasma derivatives, including 
factor VIII concentrates, factor IX concentrates, im-
munoglobulin, and albumin. In this paper, we discuss the 
current domestic status of plasma use and the related in-
surance policy of the Health Insurance Review & Assessment 
Service (HIRA), which ensures health insurance for the 
entire South Korean nation. This in turn will aid in develop-
ing a proposal for the proper use of plasma components.
CURRENT DOMESTIC STATUS OF PLASMA USE
The transfusion of plasma components in Korea began in 
earnest in the 1990s, with the establishment of blood compo-
nent therapy as an alternative to whole blood therapy. In 
2009, a total of 658,069 units of plasma were supplied from 
the Korean Red Cross Blood Center (KRCBC), which mainly 
comprised FFP (92.7%), cryoprecipitates (7.3%), and frozen 
plasma (0.1%). The KRCBC provides approximately 97% 
of all the blood components used in Korea. According to 
the Annals of Statistics from KRCBC, the total plasma supply 
gradually decreased from 2003 (663,539 units) to 2006 
(636,897 units), but then increased slightly from 2007 
(643,674 units) to 2009 (658,069 units). Among blood com-
ponents, lesser amounts of plasma are supplied compared 
with red blood cells (RBC) and platelets. In Korea, plasma 
accounts for less than 20% of all blood components supplied, 
and the proportion of plasma supplied has steadily decreased 
from 2003 (19.3%) to 2009 (15.9%) (Fig. 1). 
  Despite using 98% of total plasma components, the total 
amount of claims to HIRA from tertiary and general hospitals 
for plasma accounts for approximately 75% of the total 
plasma supply of KRCBC. Although the proportion of the 
amount of claims for plasma components to the supply of 
plasma has gradually increased over time, the remaining 
25% might be claimed mostly by automobile insurance and 
industrial accident insurance, or, in a small proportion of 
cases, is directly paid for by the patients without filing 
for claims to HIRA. As a regional emergency medical center 
of southern Gyeonggi-do, Ajou University Hospital filed 
for claims to automobile insurance or industrial accident 
insurance companies for 22.4% of the total plasma units 
used in 2009.
  According to the Annals of Statistics from HIRA, although 
the amount of plasma used has shown an annual variation, 
tertiary hospitals have used approximately twice as many 
plasma components as have general hospitals (1.86-1.96 
folds), indicating that the main source of plasma con-
sumption is tertiary hospitals. The average RBC-to-plasma 
transfusion ratio is 2.31：1, with higher plasma usage in 
tertiary hospitals (1.9：1) than in general hospitals (3：1). 
The units of plasma per plasma claim (plasma units/claim) 
was maintained at 7.6-7.7 units between 2005 and 2008, 
with a slight annual variation. The “plasma units/claim” 
was higher in tertiary hospitals (7.8 units) than in general 
hospitals (7.4 units), and was two times higher than that 
for RBCs (3.8 units), despite the fact that the amount of 
plasma used was only half that of RBCs. Regardless of the Korean J Hematol 2010;45:147-9.
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Fig. 1. Proportions (%) of supplied units of blood components for 
transfusion in Korea for the years 2003 to 2009. WB, whole blood; RBC, 
red blood cell components; Plasma, fresh frozen plasma and 
cryoprecipitates; PC, platelet concentrates; A-PLT, apheresis platelets.
Table 1. Proportion (%) and mean units of plasma used per plasma
transfusion in tertiary and general hospitals in Korea according to 
the DRG code, 2006 to 2008.
Diagnosis-related 
group code
Tertiary  General Total
% Unit % unit %
H6130 Malignancy of liver 
 without chemotherapy or 
 radiation therapy
6.8 1.16 6.5 0.75 13.3
A0530 Tracheostomy, 
 except for face, mouth, 
 and neck diagnoses with 
 ventilator
5.6 4.3 5.5 2.46 11.1
H6010 Cirrhosis and 
 alcoholic hepatitis with
 major complications
2.6 2.98 5.5 1.7 8.1
R6002 Acute leukemia, 
 age ＞17
3.2 1.81 2.4 2.47 5.6
H6410 Disorders of liver, 
 except for malignancy,
 cirrhosis, and alcoholic  
 hepatitis with major 
 complications
1.8 2.26 3 1.05 4.8
G5010 Gastroscopy for 
 major digestive diseases
1.7 0.72 2.5 0.78 4.2
fact that a smaller number of patients were transfused with 
FFP compared to RBCs, FFP-transfused patients received 
more units of FFP when compared to the amount of RBCs 
used in RBC-transfused patients.
  According to the claims filed to HIRA for transfusion 
from 2003 to 2007, the male-to-female ratio for plasma 
use was 1.8：1, indicating that men were more likely to 
receive plasma transfusion. Approximately half of the plasma 
components supplied were used for patients in their 50s 
(22.5%) and 60 s (23.3%). Plasma was most frequently used 
by the departments of internal medicine (53.2%), followed 
by general surgery (19.0%), thoracic surgery (7.9%), neuro-
surgery (6.1%), pediatrics (3.5%), obstetrics & gynecology 
(2.9%), orthopedic surgery (2.8%), emergency medicine 
(2.1%), and others (2.5%). The departments with the highest 
“plasma units/claim” were general surgery (8.4 units), in-
ternal medicine (7.3 units), and thoracic surgery (6.1 units).
  The claims filed to HIRA for transfusion in 2004 revealed 
that approximately 38% of plasma was given to patients 
with liver disease or cancer. The annual reports of HIRA 
from 2006 to 2008 describe patients with liver disease as 
the group with the highest use of plasma. Excluding the 
acute leukemia (age＞17) group, plasma use showed a declin-
ing trend in general hospitals. Table 1 shows the proportion 
(%) and mean units of plasma used per plasma transfusion 
among the disease groups categorized by diagnosis-related 
group (DRG) code in tertiary and general hospitals from 
2006 to 2008.
  The studies on blood use in Korea have reported that 
FFP is the blood component with the highest percentage 
of inappropriate transfusions. Inappropriate transfusion of 
FFP varied among hospitals, ranging from 30.7% to 59.2%, 
compared to 2.8-19.9% for RBC transfusion and 4.9-14.3% 
for platelet transfusion. These reports indicated the follow-
ing as inappropriate administrations of FFP: use without 
a specific reason in patients with burns; use as a blood 
volume expander in patients with decreased albumin levels 
or blood volume; use for nutritional support of patients 
or psychological reliefs for patients and attending physicians, 
routine use with RBC transfusions; and to facilitate healing 
of post-operative wounds. 
  T h a w e d  F F P  m u s t  b e  d i s c a r d e d ,  i f  i t  i s  s t o r e d  l o n g e r  
than 3 hours at room temperature or 24 hours in a 
refrigerator. In its evaluation of blood wastage in hospitals 
in 2008, the Division of Human Blood Safety Surveillance 
reported a high RBC wastage rate (5.1%) in institutes with 
admission capacities of 100 beds or less, and the highest 
rates of FFP wastage (2.3%) in institutes with admission 
capacities of 500 beds or more; these being a significant 
source of plasma consumption [1].
DOMESTIC INSURANCE POLICY FOR THE USE OF 
PLASMA
The exact rate of cuts on blood components is currently 
unknown because official data is not provided by HIRA. 
Nevertheless, FFP is expected to have the highest cut rates 
among blood components. However, the reported cut rates 
on claims to HIRA for blood components from a single 
tertiary hospital in 2009 were 2.06% for platelets, 1.2% 
for FFP, and 0.04% for RBCs. The low cut rates for FFP 
in comparison to platelets could be explained by the high 
number of FFP units used without claims to HIRA and 
paid for by the patients. 
  HIRA does not provide official screening criteria. This Korean J Hematol 2010;45:147-9.
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is because it is difficult to apply the same screening criteria 
to insurance claims for FFP transfusion, since each clinical 
case requiring FFP transfusion is different. Therefore, the 
medical records and laboratory findings are reviewed in 
order to decide whether plasma transfusion is needed to 
stop bleeding or whether coagulation factors should be used 
instead. The inspection personnel of HIRA are in charge 
of performing initial evaluations of all claims for blood com-
ponents and, if necessary, full-time or part-time advisory 
committee members are consulted for further review prior 
to making the final decision.
  Typical examples of cutbacks on claims for FFP were 
FFP transfusions without blood coagulation testing, patients 
with blood coagulation tests results but not supporting FFP 
transfusion, and albumin supplementation as the sole ob-
jective in patients with burns or at post-operation. Claims 
for FFP by surgical departments are frequently subjected 
to cuts, which was also apparent in the data from Ajou 
University, which revealed 86% of cuts occurred in surgical 
departments. HIRA began evaluations of the adequate use 
of blood components in general and tertiary-level hospitals 
that make claims via EDI (Electronic Data Interchange) 
billing in 2003, with yearly evaluations since 2008. Accor-
ding to the evaluation, the plasma transfusion volume index 
per diagnosis in 2008 showed tendencies of a decrease in 
tertiary hospitals and an increase in general hospitals in 
comparison with those of 2006. 
CONCLUSION
Among the blood components, the proportion of plasma 
use has steadily decreased compared to those of RBC or 
platelets. FFP is the most commonly used plasma product, 
but it is also the product with the highest inappropriate 
transfusion rate and blood disposal rate. Therefore, vigorous 
efforts by clinicians and the blood bank staffs to prevent 
wastage and misuse of FFP are needed to encourage proper 
use of FFP and to prevent wastage of valuable resources. 
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